Hoffmann-la Roche

This study follows 30 people with Type I or Type II spinal muscle atrophy who are starting or have started treatment with risdiplam. Researchers will track motor function improvements and safety over 24 months using standard tests. The goal is to see how well the drug works in ev…

This study tests how the drug ocrelizumab works in children and teens (ages 10 to under 18) with relapsing-remitting multiple sclerosis. It measures drug levels, safety, and immune effects over 48 weeks, with optional longer follow-up. The goal is to control the disease, not cure…

This study tests a new medicine called afimkibart in 100 children aged 2-17 with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining. Participants will receive the drug or a placebo, and doctors will monitor their progress over…

This study tests whether a new drug called cevostamab, combined with two standard drugs (pomalidomide and dexamethasone), works better than usual treatments for people with multiple myeloma who have already tried 1 to 3 prior therapies. About 380 adults will take part. The goal i…

This study tests whether a targeted drug called divarasib can prevent lung cancer from coming back after surgery in people with a specific gene mutation (KRAS G12C). About 400 adults with stage II-III non-small cell lung cancer who had surgery and prior chemo-immunotherapy will r…

This study is a registry that will collect information from about 3,000 people with COPD who have frequent exacerbations (flare-ups). Researchers will track how the disease progresses, what treatments patients receive, and how their quality of life changes over time. No new treat…